The CDK7 inhibitor CT7001 (Samuraciclib) targets proliferation pathways to inhibit advanced prostate cancer.
Theodora A ConstantinAnabel Varela-CarverKyle K GreenlandGilberto Serrano de AlmeidaEllen OldenLucy PenfoldSimon AngAlice OrmrodDamien A LeachChun-Fui LaiEdward K AinscowAsh K BahlDavid CarlingMatthew John FuchterSimak AliCharlotte Lynne BevanPublished in: British journal of cancer (2023)
This study supports CDK7 inhibition as a strategy to target deregulated cell proliferation and demonstrates CT7001 is a promising CRPC therapeutic, alone or in combination with AR-targeting compounds.